Research

Biohaven’s Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy

February 24, 2023
Posted in , ,

This week, Biohaven announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for taldefgrobep alfa, a novel anti-myostatin adnectin, […]

Read More ›

Cure SMA Awards $150,000 Grant to Florence Rage, PhD, at the Institute of Molecular Genetics of Montpellier

February 15, 2023
Posted in , ,

Florence Rage, PhD, was awarded $150,000 for her research project, “Deciphering the Mechanisms of RNA Transport along Axons to Understand the Progression of Spinal Muscular […]

Read More ›

Cure SMA Awards $150,000 Grant to Anton Blatnik, PhD, at The Ohio State University

February 8, 2023
Posted in , ,

Anton Blatnik, PhD, at The Ohio State University has been awarded $150,000 for his research project, “Determining Primary Splicing Changes in Spinal Muscular Atrophy.” Dr. […]

Read More ›

Cure SMA Supports Clinical Trial Readiness

January 26, 2023
Posted in ,

In recent years, the FDA-approval of three new SMA treatments has made it possible for a growing number of affected individuals to receive disease-modifying drugs. […]

Read More ›

Cure SMA Awards $150,000 Grant to Alberto Kornblihtt, PhD, Universidad de Buenos Aires

January 26, 2023
Posted in ,

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in SMA […]

Read More ›

Cure SMA Holds Patient-Led Listening Session with FDA

October 4, 2022
Posted in , , ,

On Thursday, August 4, 2022, six members of the SMA community had the opportunity to talk directly with the U.S. Food and Drug Administration (FDA) […]

Read More ›

Cure SMA Holds Patient-Led Listening Session with FDA

October 4, 2022
Posted in , ,

On Thursday, August 4, 2022, six members of the SMA community had the opportunity to talk directly with the U.S. Food and Drug Administration (FDA) […]

Read More ›

Cure SMA Launches Benefit-Risk Survey to Assess Patient Perspective on Treatment Possibilities and Risks

September 8, 2022
Posted in , ,

Cure SMA is conducting a survey to understand our community’s perspectives on treatment possibilities and tolerance for the side effects of currently available and planned […]

Read More ›

2022 Cure SMA Annual Research Meeting Summaries – Special and Clinical Research Session

August 15, 2022
Posted in , ,

In June, SMA researchers and clinicians from around the world met in Anaheim, CA, for the 2022 Annual SMA Research and Clinical Care Meeting. There […]

Read More ›

2022 Cure SMA Annual Research Meeting Summaries – Basic Research Sessions

August 15, 2022
Posted in , ,

In June, SMA researchers and clinicians from around the world met in Anaheim, CA, for the 2022 Annual SMA Research and Clinical Care Meeting. There […]

Read More ›
Scroll to Top